Connect your AI

Omeros OMER Derivative Liability, Noncurrent

Derivative Liability, Noncurrent at other companies

Spyre Therapeutics, Inc.SYRE

——

Other financials

Income statement

Revenue$9.9M—

Gross profit$29.7M—

Operating income-$40.9M-9.2%

Net income$56.1M+268%

EPS (diluted)-$0.59-20.4%

Balance sheet

Cash & equivalents$1.9M-55.3%

Total debt$13.5M-30.3%

Total equity-$63.3M+70.3%

Total assets$286.2M+21.7%

Cash flow

Operating cash flow-$14.5M+59.5%

CapEx--100%

Free cash flow-$14.5M+59.6%

Valuation

Market cap$775.86M+313%

P/S8.6×—

Profitability

Gross margin98.9%—

Operating margin-181.8%—

Net margin-136.6%—

FCF margin-121.6%—

Returns & leverage

Return on equity86.6%—

Debt / equity0.3×-1.1×

Current ratio3×+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's derivative liability, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Omeros's derivative liability, noncurrent?: Omeros (OMER) reported derivative liability, noncurrent of $84.03M in Q1 2026.